Skip to main content
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SNOA ISIN · US83558L2043 US Manufacturing
Open in API
Filings indexed 951 across all filing types
Latest filing 2018-06-13 Earnings Release
Country US United States of America
Listing US SNOA

About Sonoma Pharmaceuticals, Inc.

https://sonomapharma.com/

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products based on its patented Microcyn® Technology, a stabilized hypochlorous acid (HOCl) platform. With over 20 years of experience, the company produces a range of prescription and over-the-counter solutions for advanced wound care, dermatology, animal health, and eye care. Its products are designed to manage various conditions by promoting healing and reducing the risk of infection. The portfolio serves healthcare professionals in settings like hospitals and nursing homes, as well as consumers for at-home use.

Recent filings

Filing Released Lang Actions
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 13, 2018, reporting the issuance of a press release announcing financial results for the fiscal quarter and year ended March 31, 2018. It includes references to a press release (Exhibit 99.1) and a presentation (Exhibit 99.2) related to the earnings announcement. The text explicitly states that the press release and presentation are furnished but not filed, and the document itself is a current report under the Securities Exchange Act. The content corresponds to an initial announcement of quarterly and annual financial results, which aligns with the definition of an Earnings Release (ER). The document length is 4313 characters, which is relatively short and typical for an 8-K earnings release filing. Therefore, the appropriate classification is Earnings Release (ER).
2018-06-13 English
CURRENT REPORT
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 4, 2018, by Sonoma Pharmaceuticals, Inc. It announces the entry into a material definitive agreement, specifically a 5-year exclusive license and distribution agreement with EMS S.A. The content focuses on the description of this agreement and does not contain financial statements or detailed financial performance data. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing used to disclose significant corporate events outside of regular periodic reports. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-06-05 English
OWNERSHIP DOCUMENT
Director's Dealing
2018-06-01 English
OWNERSHIP DOCUMENT
Director's Dealing
2018-06-01 English
OWNERSHIP DOCUMENT
Director's Dealing
2018-06-01 English
OWNERSHIP DOCUMENT
Director's Dealing
2018-03-14 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.